AstraZeneca (AZN, Financial) has announced that Tezspire (tezepelumab) has successfully met the primary endpoints in the Phase III WAYPOINT study for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The treatment group exhibited significant reductions in nasal polyps and alleviation of nasal congestion symptoms.
Tezepelumab is a first-in-class monoclonal antibody jointly developed by AstraZeneca and Amgen. It works by inhibiting thymic stromal lymphopoietin (TSLP), a critical epithelial cytokine involved in inflammatory responses related to diseases such as asthma, CRSwNP, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE). By blocking TSLP, Tezspire prevents immune cells from releasing pro-inflammatory cytokines, effectively treating associated conditions.
Currently, Tezepelumab is approved in the United States for the treatment of severe asthma. It is undergoing Phase III clinical trials in China and is being developed for other potential indications, including COPD and EoE.
